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ABSTRACT 
The Brazilian National Regulatory Agency for Private Health Insurance 
and Plans has recently published a technical note defining the criteria for 
the coverage of genetic testing to diagnose hereditary cancer. In this study 
we show the case of a patient with a breast lesion and an extensive history 
of cancer referred to a private service of genetic counseling. The patient 
met both criteria for hereditary breast and colorectal cancer syndrome 
screening. Her private insurance denied coverage for genetic testing 
because she lacks current or previous cancer diagnosis. After she appealed 
by lawsuit, the court was favorable and the test was performed using 
next-generation sequencing. A deletion of MLH1 exon 8 was found. We 
highlight the importance to offer genetic testing using multigene analysis 
for noncancer patients.
DESCRIPTORS: Supplemental Health. Health Maintenance 
Organizations. Private Health Care Coverage. Genetic Testing. 
Genetic Predisposition to Disease. Neoplasms, diagnosis. 
Comunicação Breve DOI:10.1590/S0034-8910.2015049005988
Tirzah Braz Petta LajusI,II
2 Genetic testing for cancer in Brazil Lajus TBP
Since January 2014, the Agência Nacional de Saúde 
(ANS – Brazilian National Regulatory Agency for 
Private Health Insurance and Plans) has included 22 new 
guidelines (Anexo da Nota 876/GGRAS/DIPRO/ANS) 
concerning the utilization of DNA sequencing and of 
fluorescence in situ hybridization for microduplications 
and microdeletions to diagnose 29 genetic diseases. 
Herein we show a report of a patient that did not meet 
the ANS criteria to benefit from genetic testing, but did 
meet international guidelines, and was diagnosed with a 
MLH1 germline mutation. We highlight that the patient 
inclusion criteria and for molecular methodology of the 
ANS guidelines should be reviewed.
This article highlights the importance of discussing the 
criteria for molecular diagnosis in the Brazilian health 
care system.
CASE REPORT AND DISCUSSION
A 36-year-old patient was referred to a private genetic 
counseling service because, besides an extensive 
family history of cancer, she had a 2.0 cm lump 
detected in her right breast, as assessed by Magnetic 
Resonance Imaging, of Breast Imaging Reporting and 
Data System (BIRADS) category 4. The biopsy by fine 
needle aspiration showed a ductal proliferative breast 
lesion. The patient had a high risk for breast cancer 
and family history of cancer, with kindred diagnosed 
before the age of 50 years. The analysis of her pedi-
gree showed an autosomal dominant disorder from 
her paternal side (Figure) with early onset cases of 
colon adenocarcinoma, gastric, lung, prostate and 
pancreas cancer.
According to the ANS guideline, the patient did not 
meet the criteria to be tested for germline mutations 
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because (i) she had no current or previous cancer diag-
nosis, (ii) she was not of Ashkenazi jewish origin, and 
(iii) there were no known mutations in her family. It 
is important to highlight that the patient was informed 
she was not the perfect index patient for family genetic 
counseling since she was not diagnosed with cancer; 
thus, her result was limited to individual genetic coun-
seling, i.e., a negative result for presence of mutation 
would not mean the absence of mutation in her family.
Since Brazil lacks a specific guideline to screen hered-
itary cancer, the worldwide applied United States 
National Comprehensive Cancer Network (NCCN) 
is routinely used. It comprises recommendations on 
the prevention, diagnosis, and management of malig-
nancies across the continuum of care. The NCCN 
Guidelines incorporate real-time updates in keeping 
with the rapid advancements in the field of cancer 
research and management. For hereditary nonpolyposis 
colorectal cancer (HNPCC), or Lynch syndrome (LS), 
the patient should meet revised Amsterdam criteria8 or 
revised Bethesda criteria.7
Genetic counseling consultation is a health service 
that provides information and support to people who 
have or may be at risk for genetic disorders. It also 
addresses patients’ specific questions and concerns. 
The consultation is held by a multidisciplinary team 
with a psychologist, a medical doctor and a geneticist. 
After careful medical data collection and considering 
the patient history, she met NCCN Genetic/Familial 
High-Risk Assessment criteria both for breast and 
ovarian and for colorectal cancer, contrary to the ANS 
guideline. She was considered eligible for genetic 
screening, and the genes implicated with hereditary 
breast and ovarian cancer and hereditary nonpolyposis 
colorectal cancer were chosen to be sequenced.
Figure. Pedigree of the index patient (indicated by an arrow). Cancer types are described in the figure.
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After the oncologist request for genetic testing, the 
patient contacted her private insurance and had her 
request denied because she had no current or previous 
cancer diagnosis. The patient then appealed the court 
decision and had the DNA sequencing analysis.
The patient and her family received genetic counseling 
and written informed consent was obtained. Genomic 
DNA was extracted from saliva using Oragene DNA 
(DNA Genotek, Canada). Next-generation DNA 
sequencing was performed in Illumina MiSeq using 
TruSight Cancer Sequencing Panel, which targets 
94 genes that predispose to several cancers (e.g., 
breast, colorectal, lung), including rare cancers. In 
addition, the panel includes 284 single-nucleotide 
polymorphisms suspected to be associated with cancer 
by genome-wide association studies. The probe set 
was designed to enrich for > 1,700 exons, span-
ning 94 genes of interest, and targets a total of 255 
kb of the human genome. The 80-mer probes target 
libraries of approximately 500 bp (insert size of 300 
bp), enriching 350-650 bases centered symmetri-
cally around the midpoint of the probe, with a recom-
mended mean coverage of 100%. This means that 
the kit covers exonic and noncoding DNA in exon-
flanking regions, on average 50 bp. This test analyses 
both coding regions for genes involved in hereditary 
breast, ovarian, and nonpolyposis colorectal cancer 
(ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1 
CHEK2, MLH1, MSH2, MSH6, MUTYH, PALB2, 
PMS2, PTEN, RAD51C, RAD51D and TP53).
The DNA analysis method registered in the ANS 
guideline is sequencing of the coding regions by Sanger.5 
In the Brazilian Hierarchical Classification of Medical 
Procedures, the code TUSS22 N 40.50.31-00 represents 
Sanger sequencing of 100 bp per patient, per sample. 
The gene BRCA1 (Online Mendelian Inheritance in 
Man [OMIM 113705]) has 81,189 bp, and BRCA2 
(OMIM 600185) has 84,193 bp, both totaling 
165,382 bp, which means 1,600 times the procedure 
registered at the aforementioned classification. In 
Brazil, the cost to sequence the genes BRCA1 and 
BRCA2 by Sanger is 4,000 BRL (around 1,120 USD), 
while sequencing 69 genes by NGS costs 6,900 BRL 
(around 1,630 USD). The difference is negligible 
for the amount of studied genes. However, it is very 
important to target the genes of interested that will be 
analyzed, furthermore when the goal is to diagnose 
cancer predisposition syndromes for which few guide-
lines are available.
The result found by next-generation DNA sequencing 
from the index patient has showed a deletion in 
MLH1 exon 8 (OMIM 120436). This mutation was 
not previously described in the National Center for 
Biotechnology Information (http://www.ncbi.nlm.nih.
gov) or in the Leiden Open Variation Database (http://
databases.lovd.nl/genomed/home); however, large exon 
deletion is often classified as pathogenic and related to 
hereditary nonpolyposis colorectal cancer.
Hereditary nonpolyposis colorectal cancer is a genet-
ically heterogeneous disease subdivided into (1) 
Lynch syndrome I, or site-specific colonic cancer, and 
(2) Lynch syndrome II, or extracolonic cancer, particu-
larly carcinoma of the stomach, endometrium, biliary 
and pancreatic system, and urinary tract.2,4 About 50.0% 
from all hereditary nonpolyposis colorectal cancer with 
identified mutation is associated with MLH1, which 
codes a protein involved in DNA repair.
Several guideline protocols have been developed to 
identify families with inherited colorectal cancer and/
or Lynch syndrome. The Amsterdam I criteria were 
initially coined to identify families with colorectal 
cancer. The finding of extracolonic cancers, especially 
endometrial cancer, in Lynch syndrome prompted 
introduction of the revised Amsterdam criteria.8 
The Bethesda guidelines included testing for tumor 
marker microsatellite instability (MSI), and the revised 
Bethesda criteria7 specified all cancers known at the 
time to be associated with the syndrome. Prostate cancer 
has also been shown to be part of the syndrome.6
The clinical testing criteria for hereditary nonpolyposis 
colorectal cancer currently applied (based on personal 
and family history) meets revised Bethesda criteria 
or revised Amsterdam criteria, in which at least three 
relatives must have had a cancer associated with Lynch 
syndrome (colorectal, cancer of endometrium, small 
bowel, ureter or renal-pelvis); all of the following 
criteria should be present:
• One must be a first-degree relative of the other two;
• At least two successive generations must be affected;
• At least one relative with cancer associated with 
LS should be diagnosed before the age of 50 years;
• Familial adenomatous polyposis should be excluded 
in colorectal cancer cases (if any);
• Tumors should be verified whenever possible.
Lynch and de la Chapelle3 provided an extensive 
review of clinical features, pathology, molecular 
genetics, surveillance, and management in hereditary 
nonpolyposis colorectal cancer. They emphasized the 
importance of ascertaining cancer of all anatomic sites 
as well as noncancer phenotypic stigmata in assessing 
a family cancer history to allow defining the specific 
colorectal cancer syndrome concerned. In this first anal-
ysis, mutation carriers had an overall 50.4% cumula-
tive risk of developing colorectal cancer by the age of 
70 years (54.3% in men and 46.3% in women). The risk 
for men with MLH1, MSH2, and MSH6 mutations was 
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57.9%, 53.6%, and 36.2%, respectively, whereas for 
women it was 50.2%, 47.7%, and 18.3%, respectively.1
The molecular diagnosis of hereditary nonpolyposis 
colorectal cancer in the index patient had an important 
role in individual and familial follow-up. The patient 
had been monitored only by a breast surgeon; however, 
after the result, the gastrointestinal tract was the center 
of the problem and she looked for a proctologist and 
gastroenterologist. Her family was aware of the hered-
itary risk for colorectal cancer and for extracolonic 
cancers, especially endometrial cancer.
The impact of genetic counseling in this family 
highlights the importance to track individuals at risk 
for hereditary cancer, in spite of the patient lacking a 
previous or current diagnosis of cancer. The main objec-
tive of DNA sequencing to identify germline mutations 
is to offer early detection of cancer; nevertheless, in 
some cases, prophylactic surgery should be recom-
mended. The earliest the cancer diagnosis is concluded, 
the better is the patient prognosis.
Furthermore, early diagnosis can reduce treatment costs. 
For follow-up screening, this patient will undergo annual 
mammogram, breast ultrasound or magnetic resonance 
imaging, and colonoscopy, but certainly the costs for 
these exams are lower than those for cancer treatment, 
which can be around 10,000 BRL (around 2,850 USD) 
per month for Herceptin (www.brasindice.com.br).
In conclusion, this case report highlights the importance 
of performing multigene analysis by next-generation 
DNA sequencing in families with cancers at multiple 
sites, which reinforces the need to update the ANS 
guideline in Brazil. Herein, the patient’s needs and 
concerns had changed after the molecular diagnosis, 
since the family was concerned only about breast 
annual exams, and thereafter they were encouraged to 
be followed also by a gastroenterologist. The molecular 
diagnosis by deep sequencing gave the opportunity for 
genetic counseling and thus general medical awareness 
will be performed.
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